FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555465656> ?p ?o ?g. }

• W2555465656 abstract "Abstract Abstract 446 Background: The outcome of myeloma (MM) patients who are no longer responding to thalidomide, lenalidomide or bortezomib is poor, with a median event-free survival of 5 months and median overall survival (OS) of 9 months (Kumar SK et al, Leukemia 2012). The newer immunomodulatory drug pomalidomide, has shown significant activity in these clinical conditions. Aims: We assessed dosing, efficacy and safety of pomalidomide-cyclophosphamide-prednisone (PCP) in MM patients relapsed/refractory to lenalidomide. Methods: Pomalidomide was administered in doses ranging from 1 to 2.5 mg/day on days 1–28, cyclophosphamide at 50 mg every other day on days 1–28 and prednisone at 50 mg every other day on days 1–28 for 6 cycles, followed by maintenance therapy with pomalidomide-prednisone. Thromboprophylaxis with aspirin 100 mg/day or low-molecular weight heparin was recommended at physician's discretion. Results: The maximum tolerated dose (MTD) of pomalidomide was defined as 2.5 mg/day. Fifty-two patients were enrolled at the MTD and evaluated after completing at least 1 PCP cycle. Median age was 69 years (range 41–83). The median time from diagnosis to enrolment was 55 months (range 15–203). Best responses to PCP included 6% of complete response (CR), 19% of at least very good partial response (VGPR), 54% of at least partial response (PR) and 75% of at least minimal response (MR). Time to PR was rapid (median 1.8 months). After a median follow-up of 11 months (range 1–18), 1-year progression-free survival (PFS) and OS rates were 52% and 78%, respectively. PFS was not significantly different in patients with high-risk cytogenetic compared with patients with standard-risk disease and in patients younger or older than 75 years. Toxicities were primarily hematologic and included grade 4 neutropenia (13%) and thrombocytopenia (4%). At least grade 3 non-hematologic toxicities included infections (8%), rash (6%) and neurologic (6%). Thromboembolism occurred in 1 patient. Four patients discontinued treatment for toxicity (2 infections, 1 neurologic and 1 hepatic toxicity). Conclusions: PCP induced high response rates and prolonged PFS after prior exposure to lenalidomide and bortezomib (Table), without adding significant toxicity. PCP could be considered a valuable salvage option for pre-treated MM patients. Disclosures: Palumbo: Celgene: Consultancy, Honoraria. Larocca:Celgene: Honoraria. Sciacca:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Guglielmelli:Celgene: Honoraria. Giuliani:Celgene: Research Funding. Boccadoro:Celgene: Consultancy, Honoraria." @default.
• W2555465656 created "2016-11-30" @default.
• W2555465656 creator A5004911570 @default.
• W2555465656 creator A5015790909 @default.
• W2555465656 creator A5016794322 @default.
• W2555465656 creator A5017455719 @default.
• W2555465656 creator A5018139001 @default.
• W2555465656 creator A5023517351 @default.
• W2555465656 creator A5025882756 @default.
• W2555465656 creator A5027385305 @default.
• W2555465656 creator A5027869659 @default.
• W2555465656 creator A5041186061 @default.
• W2555465656 creator A5048703175 @default.
• W2555465656 creator A5053560614 @default.
• W2555465656 creator A5059967673 @default.
• W2555465656 creator A5068769311 @default.
• W2555465656 creator A5073975207 @default.
• W2555465656 creator A5076929140 @default.
• W2555465656 creator A5079910766 @default.
• W2555465656 creator A5083314734 @default.
• W2555465656 date "2012-11-16" @default.
• W2555465656 modified "2023-09-26" @default.
• W2555465656 title "Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma" @default.
• W2555465656 doi "https://doi.org/10.1182/blood.v120.21.446.446" @default.
• W2555465656 hasPublicationYear "2012" @default.
• W2555465656 type Work @default.
• W2555465656 sameAs 2555465656 @default.
• W2555465656 citedByCount "7" @default.
• W2555465656 countsByYear W25554656562013 @default.
• W2555465656 countsByYear W25554656562014 @default.
• W2555465656 crossrefType "journal-article" @default.
• W2555465656 hasAuthorship W2555465656A5004911570 @default.
• W2555465656 hasAuthorship W2555465656A5015790909 @default.
• W2555465656 hasAuthorship W2555465656A5016794322 @default.
• W2555465656 hasAuthorship W2555465656A5017455719 @default.
• W2555465656 hasAuthorship W2555465656A5018139001 @default.
• W2555465656 hasAuthorship W2555465656A5023517351 @default.
• W2555465656 hasAuthorship W2555465656A5025882756 @default.
• W2555465656 hasAuthorship W2555465656A5027385305 @default.
• W2555465656 hasAuthorship W2555465656A5027869659 @default.
• W2555465656 hasAuthorship W2555465656A5041186061 @default.
• W2555465656 hasAuthorship W2555465656A5048703175 @default.
• W2555465656 hasAuthorship W2555465656A5053560614 @default.
• W2555465656 hasAuthorship W2555465656A5059967673 @default.
• W2555465656 hasAuthorship W2555465656A5068769311 @default.
• W2555465656 hasAuthorship W2555465656A5073975207 @default.
• W2555465656 hasAuthorship W2555465656A5076929140 @default.
• W2555465656 hasAuthorship W2555465656A5079910766 @default.
• W2555465656 hasAuthorship W2555465656A5083314734 @default.
• W2555465656 hasConcept C121332964 @default.
• W2555465656 hasConcept C126322002 @default.
• W2555465656 hasConcept C141071460 @default.
• W2555465656 hasConcept C142424586 @default.
• W2555465656 hasConcept C2776063141 @default.
• W2555465656 hasConcept C2776364478 @default.
• W2555465656 hasConcept C2776694085 @default.
• W2555465656 hasConcept C2776755627 @default.
• W2555465656 hasConcept C2777478702 @default.
• W2555465656 hasConcept C2778524551 @default.
• W2555465656 hasConcept C2778720950 @default.
• W2555465656 hasConcept C2779609412 @default.
• W2555465656 hasConcept C71924100 @default.
• W2555465656 hasConcept C87355193 @default.
• W2555465656 hasConcept C90924648 @default.
• W2555465656 hasConceptScore W2555465656C121332964 @default.
• W2555465656 hasConceptScore W2555465656C126322002 @default.
• W2555465656 hasConceptScore W2555465656C141071460 @default.
• W2555465656 hasConceptScore W2555465656C142424586 @default.
• W2555465656 hasConceptScore W2555465656C2776063141 @default.
• W2555465656 hasConceptScore W2555465656C2776364478 @default.
• W2555465656 hasConceptScore W2555465656C2776694085 @default.
• W2555465656 hasConceptScore W2555465656C2776755627 @default.
• W2555465656 hasConceptScore W2555465656C2777478702 @default.
• W2555465656 hasConceptScore W2555465656C2778524551 @default.
• W2555465656 hasConceptScore W2555465656C2778720950 @default.
• W2555465656 hasConceptScore W2555465656C2779609412 @default.
• W2555465656 hasConceptScore W2555465656C71924100 @default.
• W2555465656 hasConceptScore W2555465656C87355193 @default.
• W2555465656 hasConceptScore W2555465656C90924648 @default.
• W2555465656 hasLocation W25554656561 @default.
• W2555465656 hasOpenAccess W2555465656 @default.
• W2555465656 hasPrimaryLocation W25554656561 @default.
• W2555465656 hasRelatedWork W172652486 @default.
• W2555465656 hasRelatedWork W1968654086 @default.
• W2555465656 hasRelatedWork W1973888964 @default.
• W2555465656 hasRelatedWork W1975916512 @default.
• W2555465656 hasRelatedWork W1992470642 @default.
• W2555465656 hasRelatedWork W2059876129 @default.
• W2555465656 hasRelatedWork W2066800926 @default.
• W2555465656 hasRelatedWork W2123159083 @default.
• W2555465656 hasRelatedWork W2140579395 @default.
• W2555465656 hasRelatedWork W2516105277 @default.
• W2555465656 hasRelatedWork W2521999181 @default.
• W2555465656 hasRelatedWork W2525525075 @default.
• W2555465656 hasRelatedWork W2527546807 @default.
• W2555465656 hasRelatedWork W2559916328 @default.
• W2555465656 hasRelatedWork W2562170224 @default.
• W2555465656 hasRelatedWork W2574929711 @default.
• W2555465656 hasRelatedWork W2575516876 @default.
• W2555465656 hasRelatedWork W2591035438 @default.

• next